OnKure Therapeutics (OKUR) Cash from Financing Activities (2020 - 2026)

OnKure Therapeutics (OKUR) has 7 years of Cash from Financing Activities data on file, last reported at $146.0 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 189709.09% year-over-year to $146.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146.2 million (up 26.02% YoY) and the FY2025 annual result came in at $163000.0, down 99.86% from the prior year.
• Cash from Financing Activities advanced to $146.0 million in Q1 2026, from $240000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $146.0 million in Q1 2026 to a low of -$11.9 million in Q4 2023.
• A 5-year average of $21.1 million and a median of $173000.0 in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 3751.69% — and 2026, when it surged 189709.09%.
• Tracing OKUR's Cash from Financing Activities over 5 years: stood at $325000.0 in 2022, then plunged by 3751.69% to -$11.9 million in 2023, then jumped by 1028.93% to $110.2 million in 2024, then sank by 99.78% to $240000.0 in 2025, then soared by 60732.92% to $146.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $146.0 million (Q1 2026), $240000.0 (Q4 2025), and -$77000.0 (Q1 2025), per Business Quant data.